{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.77","value":"87.9"},{"groupId":"OG001","spread":"15.36","value":"87.1"},{"groupId":"OG002","spread":"15.72","value":"87.0"}]}],"title":"Interfered with general activity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.17","value":"85.4"},{"groupId":"OG001","spread":"24.16","value":"75.8"},{"groupId":"OG002","spread":"17.65","value":"81.8"}]}],"title":"Interfered with mood"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.08","value":"91.5"},{"groupId":"OG001","spread":"11.77","value":"93.0"},{"groupId":"OG002","spread":"10.80","value":"92.3"}]}],"title":"Interfered with normal work"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.62","value":"82.2"},{"groupId":"OG001","spread":"25.92","value":"77.9"},{"groupId":"OG002","spread":"21.27","value":"80.6"}]}],"title":"Interfered with relations with other people"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.46","value":"93.0"},{"groupId":"OG001","spread":"15.81","value":"92.3"},{"groupId":"OG002","spread":"9.28","value":"93.3"}]}],"title":"Interfered with sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.24","value":"77.8"},{"groupId":"OG001","spread":"27.84","value":"68.7"},{"groupId":"OG002","spread":"23.08","value":"76.4"}]}],"title":"Interfered with enjoyment of life"}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"description":"The impact of vaginal dryness for activities of daily living (ADL) were measured by the numerical analogue scales at baseline and through the six weeks of treatment. The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL. The average AUC values were calculated by dividing 6 from AUC values for participants who completed item on all 6 weeks. If a participant completed the item at baseline, week 1, 2 and 3 but did not complete the item at week 4 to week 6, the AUC values of the item was prorated, which is (((AUC values \\* 6) / 3) / 6). The average pro-rated AUC scores was compared in each of the Pilocarpine arms against the collective placebo arm.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.","id":"OG000","title":"Collective Placebo"},{"description":"Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.","id":"OG001","title":"Pilocarpine 2 Times Per Day"},{"description":"Patients receive 5mg of Pilocarpine 4 times per day for 6 weeks.","id":"OG002","title":"Pilocarpine 4 Times Per Day"}],"paramType":"MEAN","populationDescription":"Includes all participants that reported a baseline value and at least one value after baseline (i.e. week 3, 4, 5 or 6).","reportingStatus":"POSTED","timeFrame":"Baseline to Week 6","title":"Average AUC Summary Statistics for the Impact of Vaginal Dryness for Activities of Daily Living","type":"SECONDARY","unitOfMeasure":"units on a scale"}